CAREDX, INC. vs NATERA, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CDNA and NTRA diverge most: on operating margin, CDNA reads 85.8% and NTRA reads -10.1%; on net margin, CDNA reads 24.2% and NTRA reads -7.1%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | CDNA | NTRA |
|---|---|---|
| Price | $63.64 | $400.47 |
| Market cap | $3.3B | $57.4B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | 30.7 | — |
| P/B | 7.74 | 31.50 |
| P/S | 7.19 | 21.20 |
| EV/EBITDA | 25.2 | — |
| Revenue growth | +34.3% | +37.8% |
| Operating margin | 85.8% | -10.1% |
| Net margin | 24.2% | -7.1% |
| Return on equity | 26.1% | -10.6% |
| Return on assets | 20.8% | -7.2% |
| Return on invested capital | 24.6% | -11.1% |
| FCF yield | 2.7% | 0.1% |
| Debt / equity | 0.00 | 0.04 |
| Current ratio | 4.58 | 3.00 |
| Altman Z (solvency) | 6.99 | 5.88 |
| Piotroski F (quality) | 5 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.